Catalyst Crew Technologies Corp. has submitted a corporate action request to the Financial Industry Regulatory Authority seeking approval to change its name to LataMed AI Corp. and its trading symbol. The proposed change aims to better reflect the company's strategic direction following its transition toward artificial intelligence-enabled healthcare technology, with an initial focus on Latin America.
The company's Board of Directors and majority shareholder approved the proposed corporate action in accordance with Nevada law. The change does not involve any reverse stock split, forward stock split, recapitalization, change to authorized capital, or other modification to the company's capital structure. The issued and outstanding share count will remain unchanged, and the name and symbol change will not affect shareholders' ownership interests, requiring no action from existing shareholders.
Upon FINRA approval, the company intends to file a Certificate of Amendment with the Nevada Secretary of State to effect the corporate name change. The proposed changes would become effective upon completion of required corporate filings and publication by FINRA on the Daily List. Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that the proposed name change is intended to better align the company's public identity with its healthcare technology strategy and long-term market focus.
No assurance can be given that FINRA will approve the proposed name change, the requested new trading symbol, or the timing of any such approval. For more information, please visit https://catalystcrewai.com or review the company's filings with the U.S. Securities and Exchange Commission at https://www.sec.gov.
This development is significant as it signals a formal corporate rebranding aligned with the growing artificial intelligence healthcare sector, particularly in emerging markets. The shift from a generic technology name to LataMed AI Corp. clearly communicates the company's specialized focus on AI-driven healthcare solutions for Latin America, potentially attracting investors interested in this specific niche. The name change could enhance market recognition and better position the company within the competitive digital health landscape.
The announcement matters because corporate rebranding often precedes strategic initiatives and can indicate management's confidence in a new business direction. For the healthcare technology industry, it highlights the increasing convergence of artificial intelligence and healthcare services in emerging markets, where technology adoption could address systemic challenges. Investors should note that while the name change reflects strategic intent, the company remains a development-stage enterprise that has not generated revenues from its newly announced business direction, as detailed in its SEC filings.
